RxDoctor Payments DataLook up a doctor →

Thomas Robeson, MD

Family Medicine · Newport News, VANPI 1982641171

Payments from drug & device makers

$33,777in general payments, 2019–2025

Across 1,470 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$5K
  • Amgen$4K
  • AstraZeneca$4K
  • AbbVie$3K
  • Novo Nordisk$2K
  • GSK$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$7,60023%
  • Travel & lodging$280%
  • Food & beverage$25,87977%
  • Education$2691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC87$5,324
Amgen109$3,694
AstraZeneca(2 entities)95$3,584
AbbVie(2 entities)243$2,904
Novo Nordisk93$2,084
GSK82$1,407
Pfizer105$1,364
Johnson & Johnson43$1,313
Boehringer Ingelheim46$1,107
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC80$946
Radius Health, Inc.34$728
Esperion Therapeutics, Inc.11$700
Astellas Pharma US Inc20$633
Amarin Pharma, Inc.42$556
Otsuka America Pharmaceutical, Inc.24$466
Axsome Therapeutics, Inc.24$461
Biohaven Pharmaceutical Holding Company Ltd.11$454
Novartis23$404
Eisai Inc.15$375
Supernus Pharmaceuticals, Inc.28$373
Biohaven Pharmaceuticals, Inc.12$346
Merck23$282
Avanir Pharmaceuticals, Inc.5$271
Bayer16$269
Teva Pharmaceuticals USA, Inc.10$258
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$218
Clarus Therapeutics Inc.6$166
Lundbeck LLC9$165
Mannkind Corporation9$162
Mylan Specialty L.p.8$149
Antares Pharma, Inc.9$142
Exact Sciences7$135
Sanofi-aventis U.S. LLC8$125
Takeda Pharmaceuticals U.S.A., Inc.9$122
Irhythm Technologies, Inc.5$117
Kowa Pharmaceuticals America, Inc.8$114
Kaleo, Inc.7$111
Dexcom, Inc.5$110
Sumitomo Pharma America, Inc.6$107
Amneal Pharmaceuticals LLC6$97
Shield Therapeutics Inc1$87
Endo Pharmaceuticals Inc.6$83
Sunovion Pharmaceuticals Inc.4$70
Nestle Healthcare Nutrition Inc.3$59
Abbott3$58
E.r. Squibb & Sons, L.L.C.4$57
Xeris Pharmaceuticals, Inc.3$57
Novavax Inc2$49
Genentech USA, Inc.3$48
Vanda Pharmaceuticals Inc.2$48
ARS Pharmaceuticals Operations, Inc.2$47
Idorsia Pharmaceuticals US Inc2$44
Alkermes, Inc.2$43
Organon2$42
VBI Vaccine (delaware) Inc.2$40
Viatris Specialty LLC2$40
Regeneron Healthcare Solutions, Inc.2$40
Shire North American Group Inc2$35
Sanofi Pasteur Inc.2$34
Intuity Medical Inc2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,777 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$517,261
Medicare patients
682
Services billed
23,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$163,829
FarxigaDapagliflozin Propanediol136$145,093
EliquisApixaban118$117,036
JardianceEmpagliflozin65$75,866
TrulicityDulaglutide44$68,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$62,030
XareltoRivaroxaban59$52,257
XifaxanRifaximin12$44,835
Xultophy 100-3.6Insulin Degludec/Liraglutide27$41,092
MounjaroTirzepatide28$40,220
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$39,489
ShingrixVaricella-Zoster Ge/As01b/Pf157$34,751
ArexvyRsvpref3 Antigen/As01e/Pf108$33,807
VraylarCariprazine Hcl18$32,318
Synjardy XrEmpagliflozin/Metformin Hcl19$26,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus$2,084$216,096168 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,584$184,582172 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta$1,407$148,913349 claims
PfizerEliquis$1,364$117,036118 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$1,107$109,83597 claims
Lilly USA, LLCTrulicity, Mounjaro$5,324$108,95372 claims
AbbVieVraylar, Viberzi, Synthroid$2,904$58,035105 claims
Johnson & JohnsonXarelto$1,313$52,25759 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$946$44,83512 claims
AmgenProlia$3,694$20,69512 claims
Astellas Pharma US IncMyrbetriq$633$12,93124 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$125$11,55813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →